Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie's disease: A single-centre, preliminary prospective non-randomised study

---

Copy For Citation

ÜRE İ., Ozen A.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol.75, 2021 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 75
• Publication Date: 2021
• Doi Number: 10.1111/ijcp.13754
• Journal Name: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
• Eskisehir Osmangazi University Affiliated: Yes

Abstract

Aim There are a few types of drugs that can be used in the active phase of Peyronie's disease. Methylprednisolone is a corticosteroid with a strong anti-inflammatory effect. In this study, we aimed to evaluate the effect of intralesional low-dose methylprednisolone treatment on patients in the active phase of Peyronie's disease.